XML 68 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Compensation Expense and Related Income Tax Benefit
The compensation expense from the Company’s share-based compensation plans and associated income tax benefit, excluding the effects of excess tax benefits or shortfalls, are included in the Consolidated Statements of Operations as follows (in millions):
 Year Ended December 31,
Compensation costs and related income tax benefit202420232022
Cost of sales$$$
Selling and marketing27 16 22 
Research and development36 25 34 
General and administration38 19 34 
Total compensation expense$110 $66 $96 
Income tax benefit$18 $13 $17 
Schedule of Equity Awards Activity
A summary of the Company’s restricted and performance stock-settled awards for the years ended December 31, 2024, 2023 and 2022 is as follows:

Year Ended December 31, 2024
RSUsPSUsRSAs
UnitsWeighted-Average Grant Date Fair ValueUnitsWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of year437,379 $299.19 195,932 $334.59 433 $477.74 
Granted277,390 309.99 88,029 309.05 6,264 319.95 
Released(210,972)322.67 (35,597)482.42 (6,697)330.15 
Forfeited
(21,730)293.83 (6,418)304.52 — — 
Outstanding at end of year482,067 $295.39 241,946 $304.44 — $— 


Year Ended December 31, 2023
RSUsPSUsRSAsPSAs
UnitsWeighted-Average Grant Date Fair ValueUnitsWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of year242,732 $404.19 105,928 $406.89 46,971 $271.92 35,246 $245.79 
Granted336,168 260.31 104,620 258.57 6,640 271.77 — — 
Released(95,837)412.47 (64)482.42 (51,695)267.66 (35,171)245.82 
Forfeited(45,684)332.66 (14,552)313.74 (1,483)335.98 (75)244.97 
Outstanding at end of year437,379 $299.19 195,932 $334.59 433 $477.74 — $— 
Year Ended December 31, 2022
RSUsPSUsRSAsPSAs
UnitsWeighted-Average Grant Date Fair ValueUnitsWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of year130,009 $518.80 37,691 $482.42 154,322 $253.54 74,032 $225.34 
Granted181,351 359.02 70,777 367.16 6,122 321.03 — — 
Released(48,095)518.64 (226)482.42 (104,891)248.36 (38,671)206.62 
Forfeited(20,533)463.11 (2,314)410.80 (8,582)259.93 (115)244.62 
Outstanding at end of year242,732 $404.19 105,928 $406.89 46,971 $271.92 35,246 $245.79 
Schedule of SARs Activity
A summary of the Company’s SARs is as follows:
202420232022
SARsWeighted-Average Grant Date Exercise PriceSARsWeighted-Average Grant Date Exercise PriceSARsWeighted-Average Grant Date Exercise Price
Outstanding at beginning of year398,838 $124.96 443,476 $122.67 474,151 $121.05 
Granted— — — — — — 
Exercised(178,203)103.05 (42,957)99.39 (28,659)88.35 
Forfeited— — (976)244.15 (1,987)229.46 
Expired(2)86.80 (705)78.54 (29)205.12 
Outstanding at end of year220,633 $142.57 398,838 $124.96 443,476 $122.67 
Exercisable at end of year220,633 $142.57 385,305 $120.35 400,351 $110.14 
Schedule of Information for SARs Outstanding
The following table summarizes information about SARs outstanding as of December 31, 2024:
OutstandingExercisable
Aggregate intrinsic value (in millions)$54$54
Weighted-average remaining contractual life (in years)1.31.3